TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval

TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) and Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the European Commission (EC) has approved Alofisel (darvadstrocel), previously Cx601, for the treatment of complex perianal fistulas in adult patients with nonactive/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used after conditioning of fistula.2 This marks the first allogeneic stem cell therapy to receive central marketing authorization (MA) approval in Europe.

Read more at TiGenix website.